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Pancreatic cancer is a significant cause of cancer
mortality worldwide as the disease has advanced
significantly in patients before symptoms are evi-
dent. The signal transduction pathways that pro-
mote this rapid progression are not well under-
stood. Ack1 or TNK2, an ubiquitously expressed
oncogenic non–receptor tyrosine kinase, integrates
signals from ligand-activated receptor tyrosine ki-
nases to modulate intracellular signaling cascades.
In the present study, we investigated the Ack1 acti-
vation profile in a pancreatic cancer tumor mi-
croarray, and observed that expression levels of
activated Ack1 and pTyr284-Ack1 positively corre-
lated with the severity of disease progression and
inversely correlated with the survival of patients
with pancreatic cancer. To explore the mechanisms
by which Ack1 promotes tumor progression, we
investigated the role of AKT/PKB, an oncogene and
Ack1-interacting protein. Ack1 activates AKT di-
rectly in pancreatic and other cancer cell lines by
phosphorylating AKT at Tyr176 to promote cell sur-
vival. In addition, the Ack1 inhibitor AIM-100 not
only inhibited Ack1 activation but also suppressed
AKT tyrosine phosphorylation, leading to cell cycle
arrest in the G1 phase. This effect resulted in a
significant decrease in the proliferation of pancre-
atic cancer cells and induction of apoptosis. Collec-
tively, our data indicate that activated Ack1 could be
a prognostic marker for ascertaining early or ad-
vanced pancreatic cancer. Thus, Ack1 inhibitors
hold promise for therapeutic intervention to in-
hibit pancreatic tumor growth. (Am J Pathol 2012,
180:1386–1393; DOI: 10.1016/j.ajpath.2011.12.028)
1386Pancreatic cancer is the fourth most common cause of
cancer-related deaths in the United States.1 Median
overall survival for patients with pancreatic cancer after
resection of the tumor ranges from 15 to 20 months.
Pancreatic carcinomas often exhibit resistance to con-
ventional cytotoxic agents, and few effective chemother-
apeutic agents are currently available for the treatment of
advanced disease. New therapeutic strategies are ur-
gently needed to improve survival outcomes. Protein ki-
nases have emerged as a major therapeutic target for
various cancers including pancreatic cancer.2 Most pan-
creatic cancers (90%) express epidermal growth factor
receptor (EGFR).3 However, the phase III trial of the
EGFR inhibitor erlotinib (Tarceva) with gemcitabine re-
ported a marginal increase in the median survival of
patients: 6.4 months compared with 5.9 months for pa-
tients treated with gemcitabine alone.4 Therefore, inhibi-
tion of EGFR alone may not be sufficient for improving
survival outcomes. Inhibition of additional tyrosine ki-
nases and their signaling networks is also needed to
overcome the compensatory pathways that confer drug
resistance in pancreatic cancer.
A key downstream effector of receptor tyrosine kinase
(RTK) signaling is AKT/PKB kinase, which is required for
the growth of normal cells and is frequently activated in
many cancer types.5–7 Because of its ability to relay pro-
survival signals, AKT has emerged as a major hallmark of
tumor progression.5,7–9 AKT is frequently activated in pan-
creatic cancer, which is highly correlated with HER-2/neu
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PI3K and negatively by PTEN (phosphatase and tensin
homolog) is well studied, many of the pancreatic cell lines
and tumors expressing activated AKT had retained wild-
type PTEN.11,12 However, the precisemechanistic details of
tyrosine kinase–mediated AKT activation in cancers with
normal PTEN and PI3K activity is poorly understood.13,14
Recent studies have established alternative modes of AKT
activation, and one such kinase is Ack1.15
Ack1, also known as TNK2, is an ubiquitously ex-
pressed tyrosine kinase that is rapidly activated by a
number of activated RTKs including those mediated by
epidermal growth factor (EGF), platelet-derived growth
factor, and insulin signaling.16–19 Robust Ack1 activation
in a variety of cancer cells by multiple RTKs has been
reported; however, the role of Ack1 signaling in pancre-
atic cancer has not been explored. Ack1 is primarily
phosphorylated at Tyr284, leading to its kinase activa-
tion.16,17 The Ack1 gene is also amplified in primary lung,
ovarian, and prostate tumors, which correlates with poor
prognosis.20,21 Auto-activating mutations in Ack1 have
been reported in lung (W75R), ovarian (R99Q, E346K),
and stomach (M409I) cancers.15,16 Our earlier studies
have shown that Ack1 regulates prostate cancer progres-
sion to androgen independence by regulating the andro-
gen receptor.17–19 We have also recently uncovered an-
other major effector of Ack1, the oncogene AKT/PKB.
Ack1-mediated phosphorylation of Tyr176 in the AKT ki-
nase domain resulted in its activation, primarily assessed
by Ser473 phosphorylation, in a PI3K/PTEN-independent
manner promoting mitotic progression of the cells.15
In the present study, we demonstrated that activated
Ack1 expression monitored by Tyr284 phosphorylation is
significantly up-regulated in pancreatic intraepithelial
neoplasia (PanIN) and in biopsy specimens of advanced
metastatic pancreatic cancer. AKT Tyr176 phosphoryla-
tion gains prominence in late-stage pancreatic adenocar-
cinomas and is indicative of the severity of the disease.
Moreover, higher levels of activated Ack1 correlates with
poor survival outcomes, which suggests that Ack1/AKT
signaling may have an important role in progression of
pancreatic cancer. Toward the goal of understanding the
role of Ack1/AKT signaling on the growth of pancreatic
cells, we performed four sets of experiments. First, we
developed pancreatic TMA and performed immunohisto-
chemistry staining of pTyr284-Ack1 and pTyr176-AKT anti-
bodies. Second, we developed pTyr176-AKT monoclonal
antibodies and performed extensive characterization. Third,
we undertook large-scale synthesis of Ack1 inhibitor AIM-
100 to evaluate cytotoxicity. Fourth, we assessed sup-
pression of pTyr284-Ack1, pTyr176-AKT, and pSer473-
AKT levels in pancreatic and other tumor-derived cells
treated with AIM-100.
Materials and Methods
Cell Lines and Materials
Panc-1, CD18, HEK293, MCF-7, H292, A2780-CP, OV90,
and MDA-MB-468 cells were obtained from the AmericanType Tissue Culture Collection (Manassas, VA). Cells
were grown in DMEM (Panc-1, CD18, HEK293 and MDA-
MB-468) supplemented with 10% fetal bovine serum and
penicillin or streptomycin. H292, A2780-CP, and OV90
cells were grown in RPMI 1640, and MCF-7 cells were
grown in minimal essential medium supplemented with
10% fetal bovine serum and penicillin or streptomycin.
HPNE cells were grown in DMEM (Dulbecco’s modified
Eagle’s medium; Invitrogen Corp., Carlsbad, CA) supple-
mented with 25% M3F base medium, 10% fetal bovine
serum, and penicillin or streptomycin. -Tubulin (TU-O2)
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA), anti-phospho-Ack1 (Tyr284 [Upstate]; Millipore
Corp., Billerica, MA); AKT (Cell Signaling Technology,
Inc., Beverly, MA), and actin monoclonal antibody (Ab-
cam, Inc., Cambridge, MA) were purchased commer-
cially. AIM-100 was synthesized as described earlier.19
Recombinant insulin and EGF were purchased from In-
vitrogen Corp. Control and Ack1 small-interfering RNAs
(siRNAs) were custom synthesized from Qiagen GmbH
(Hilden, Germany); the siRNA sequence information has
been described previously.15
Generation and Purification of pTyr176-AKT
Monoclonal Antibody
Two AKT peptides coupled to immunogenic carrier pro-
teins were synthesized: the phosphopeptide Ac-ATGRY-
[pY]AMKIL-Ahx-C-amide and the non-phosphopeptide
Ac-ATGRYYAMKIL-Ahx-C-amide. Two rabbits were im-
munized twice with phosphopeptide, several weeks
apart, and an enzyme-linked immunosorbent assay was
performed to determine the relative titer of serum sam-
ples against phosphorylated and non-phosphorylated
peptides. For generation of monoclonal antibodies, rabbits
were sacrificed, and splenocytes were isolated. Rabbit
monoclonal antibodies expressing clones were custom
generated by Epitomics, Inc. (Burlingame, CA). Several
clones were assessed for specificity, and one clone, 96.3,
was used for large-scale production. The cell supernatant
was used for antibody purification using a protein-A sep-
harose column (Montage Kit; Millipore Corp.).
TMA Analysis
A pancreatic TMA was used in the present study, which
was exempt from institutional review board approval be-
cause no personal information about patients was
sought. Four-micrometer sections were transferred to ad-
hesive-coated slides. The tissue array slides (four slides
including two test duplicate slides, and positive and neg-
ative controls) were stained for pTyr284-Ack1 and
pTyr176-AKT using respective rabbit polyclonal antibod-
ies. The specificity of pTyr284-Ack1 and pTyr176-AKT
antibodies for detection of activated Ack1 and Tyr-phos-
phorylated AKT, respectively, by immunohistochemistry
(TMA) staining have been previously validated in biopsy
specimens of breast and prostate tumors.15,19 The slides
were dewaxed, tissues were rehydrated, and antigen
retrieval was performed. After blocking, the samples
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tibody (1:300 dilution; Millipore Corp.) and rabbit poly-
clonal pTyr176-AKT antibody (1:25 dilution) at 4°C over-
night. The sections were incubated with biotin-labeled
secondary and streptavidin-peroxidase for 30 minutes
each (Dako A/S, Glostrop, Denmark). The samples were
developed using 3,3=-diaminobenzidine substrate (Vec-
tor Laboratories, Inc., Burlingame, CA), and counter-
stained with hematoxylin. Negative controls were in-
cluded by omitting pTyr284-Ack1/pTyr176-AKT antibody
during primary antibody incubation. The stainings were
examined in a blinded fashion by two independent pa-
thologists (D.C. and A.L). Positive reactions were scored
into four grades according to the intensity of staining: 0,
1, 2, and 3. The percentages of positive cells were
also scored into four categories: 0 (0%), 1 (1% to 33%),
2 (34% to 66%), and 3 (more than 66%). The product
of the intensity and percentage scores was used as a
final staining score.
Statistical Analysis
Spearman’s correlation coefficient was estimated to ex-
amine whether there was an increasing trend for
pTyr284-Ack1 and pTyr176-AKT insofar as various
stages of pancreatic cancer progression. Analysis of
variance was performed to examine whether the expres-
sion levels differed among various progression stages.
Boxplots were used to summarize the intensity distribu-
tion at each stage. When differences were detected, the
Tukey-Kramer method was performed to examine in
which pairs of stages the expression levels were differ-
ent. This post hoc procedure adjusts for all pairwise com-
parisons and simultaneous inference. Correlation be-
tween pTyr284-Ack1 and pTyr176-AKT was examined
using Spearman’s ranked correlation analysis. The asso-
ciation of the expression levels of pTyr284-Ack1 and
pTyr176-AKT and the overall survival of patients were
assessed using the Kaplan-Meier method. When more
than one sample was obtained from a patient, the inten-
sity of the most advanced stage was used for the survival
analysis. For pancreatic cancer data, there were 85 indi-
viduals with available pTyr284-Ack1 staining and survival
information, and 78 individuals with available pTyr176-AKT
staining and survival information. Survival differences be-
tween the groups were determined using the log-rank test,
with P  0.05 considered statistically significant.
Cell Proliferation, Drug Sensitivity, and
Apoptosis Assays
CD18, Panc-1, HPNE, OV90, MCF-7, MDA-MB466, and
MEF (mouse embryonic fibroblast) cells were untreated
or treated with 2 to 10 mol/L AIM-100 for 48 hours, and
an MTT assay was performed as previously described.19
A WST-1 cell proliferation assay was performed per the
manufacturer’s protocol (Clontech Laboratories, Inc.,
Mountain View, CA). The cell death assay was performed
using CellEvent Caspase-3/7 Green Detection Reagent
(Invitrogen Corp.).Results
To examine the role of activated Ack1 in pancreatic tumor
progression, we performed TMA analysis of clinically an-
notated pancreatic tumor samples (n  281 for pTyr284-
Ack1; n  293 for pTyr176-AKT). Tyr284 is the primary
autophosphorylation site in Ack1; hence, pTyr284-Ack1
antibodies were used to assess Ack1 activation. Earlier,
we had characterized the specificity of pTyr284-Ack1
and pTyr176-AKT polyclonal antibodies for immunohisto-
chemical detection.15 Immunohistochemical staining of
pancreatic TMA was performed using total Ack1,
pTyr284-Ack1, and pTyr176-AKT polyclonal antibodies.
The total Ack1 levels remained unchanged between nor-
mal and pancreatic carcinoma samples (Figure 1, A and
B). In contrast to normal tissue, a significant increase in
pTyr284-Ack1 expression was evident in the samples of
pancreatic carcinoma (compare Figures 1C and D).
Tyr176-phosphorylated AKT expression was also up-reg-
ulated, specifically in pancreatic carcinoma compared
with normal cells, and seemed to accumulate in the nu-
clear compartment of the cancer cell. It is consistent with
the nuclear translocation of AKT and its role in export of
the pro-apoptotic FoxO proteins for cell survival8,9 (Fig-
ure 1, E and F).
Of the 281 samples with pTyr284-Ack1 expression,
there were 114 normal, 13 PanIN, and 154 carcinomas
samples. Further, of the 293 samples with pTyr176-AKT
expression, there were 137 normal, 11 PanIN, and 145
carcinomas samples. The expression levels of these
samples were used to generate boxplots (Figure 1, G and
H). A statistically significant increase in expression of
activated Ack1 (pTyr284-Ack1) was observed, from nor-
mal to PanIN to carcinoma (  0.51, P  0.0001; Figure
1G). Similarly, AKT Tyr176 phosphorylation showed an
increasing trend among stages of progression (  0.41,
P  0.0001; Figure 1H). Analysis of variance indicated
that expression levels of both pTyr284-Ack1 and
pTyr176-AKT differed significantly between stages of
progression (P  0.0001 for each protein) (see Supple-
mental Figure S1 at http://ajp.amjpathol.org). The Tukey-
Kramer method was used to examine pairwise differ-
ences between stages, and the expression levels of
pTyr284-Ack1 were significantly lower in the normal sam-
ples compared with the PanIN (P 0.0001) and carcinoma
(P  0.0001) samples. Expression levels of pTyr176-AKT
were also significantly lower in the normal samples when
compared with the carcinoma samples (P  0.0001) (see
Supplemental Table S1 at http://ajp.amjpathol.org).
Statistical analysis showed that patients with pancre-
atic cancer with higher pTyr284-Ack1 expression levels
(with staining intensity4) had significantly worse overall
survival outcome than did those with lower expression
levels, with staining intensity 4 (P  0.02 for log-rank
test; Figure 2, A and B;see also Supplemental Table S2 at
http://ajp.amjpathol.org). We also performed survival
analysis excluding the panIN samples; the conclusion for
the log-rank test results remained the same with minor P
difference: P  0.02 for pTyr284-Ack1 and P  0.15 for
pTyr176-AKT (see Supplemental Figure S2 at http://
ajp.amjpathol.org). No significant association was observed
ta with
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vival (P  0.16; Figure 2B). However, expression of
pTyr284-Ack1 significantly correlated with pTyr176-AKT in
situ (Spearman rank correlation coefficient   0.40, P 
0.0001; Figure 2C), suggesting that in addition to AKT, Ack1
may require additional proteins to promote survival.
Normal Pancreas Pancreatic Carcinom
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Figure 1. pTyr284-Ack1 and pTyr176-AKT expressions correlate with disease
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itor, and has been shown to inhibit prostate cancer cell
proliferation.19 We established the specificity of AIM-100
by performing kinase assays in the presence of increas-
ing concentrations of AIM-100. This revealed that AIM-
100 specifically inhibits Ack1 with an IC50 (half maximal
inhibitory concentration) of 22 nmol/L, but not the other 30
kinases including PI 3-kinase subfamily members and the
three known AKT isoforms (submitted for publication).
Because of the limited availability of polyclonal anti-
bodies, we generated and characterized pTyr176-AKT
monoclonal antibodies (detailed in Materials and Meth-
ods). To test the specificity of the antibodies, HEK293
cells were transfected with constitutively active Ack1
(caAck or L487F mutant) or kinase dead Ack1 (kdAck or
K158R mutant).18 Cells were harvested, and immunoblot
analysis was performed. caAck phosphorylated AKT at
Tyr176; however, kdAck failed to phosphorylate AKT (see
Supplemental Figure S3A at http://ajp.amjpathol.org). Fur-
ther, we have reported characterization of four somatic
mutations in Ack1: R34L, R99Q, E346K, and M409I.15 We
observed that E346K mutant undergoes robust auto-ac-
tivation and causes AKT Tyr176-phosphorylation; in con-
trast, phosphorylation of Tyr176 to Phe mutant of AKT (or
Y176F) was not detected (see Supplemental Figure S3B
at http://ajp.amjpathol.org). These data indicate that the
AKT-specific rabbit monoclonal antibodies can be used
to specifically detect Tyr176-phosphorylated AKT.
Ack1 integrates signals from a variety of RTKs includ-
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tivated on stimulation of more than one RTK.16 EGF- and
insulin-stimulated pancreatic cells also exhibited Tyr176-
phosphorylation of AKT (Figure 3A and B, panel 2).
pTyr284-Ack1 and pTyr176-AKT expression was also
significantly elevated in insulin-treated breast (MCF-7)
and EGF-stimulated lung (H292) and ovarian (A2780-CP)
cancer cells (Figure 3, C–E, top two panels). On treat-
ment with the Ack1 inhibitor AIM-100, Ack1 Tyr284-phos-
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AJP April 2012, Vol. 180, No. 4creatic cell proliferation, CD18 cells were treated with 10
mol/L AIM-100 for 48 hours. Phase contrast imaging
revealed that AIM-100 treatment significantly inhibited
the growth of pancreatic cells (Figure 4A). To obtain
quantitative measurement of cell growth, an MTT assay
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ment with GI50 (absolute IC50) of approximately 7 to 8
mol/L (Figure 4B). A similar decrease in cell proliferation
was observed in two lung cancer cell lines, H292 and
H1975, on AIM-100 treatment (see Supplemental Figure
S4, A and B, at http://ajp.amjpathol.org). MEF and HPNE
cells were significantly less sensitive to AIM-100 treat-
ment with GI50 of approximately 14 to 15 mol/L.
Further, to complement inhibitor studies, CD18 cells
were transfected with Ack1 or control siRNA followed by
cell proliferation assay. Ack1 siRNA-transfected cells ex-
hibited a significant decrease in cell number as com-
pared with control siRNA-transfected cells (Figure 4, C
and D). Further, a WST-1 cell proliferation assay was
performed. In contrast to control siRNA-transfected CD18
cells, Ack1 siRNA-transfected cells exhibited a signifi-
cant decrease in cell proliferation (Figure 4E). To deter-
mine whether this decrease in cell proliferation was due
to cell cycle arrest, we performed cell cycle analysis.
Cells were untreated or treated with 5 mol/L AIM-100
and stained with propidium iodide. DNA content was
measured using flow cytometry. In contrast to untreated
cells, AIM-100 treatment increased the percentage of
cells in the G1 phase of the cell cycle by 13% and
concurrently decreased cells in the S phase by 10%
(Figure 4F), which suggests that AIM-100 treatment re-
sults in cell cycle arrest in the G1 phase.
To determine whether AIM-100 treatment induces
apoptosis, a cell death assay was performed using Cel-
lEvent Caspase-3/7 Green Detection Reagent (Invitrogen
Corp.), which consists of the DEVD peptide sequence
conjugated to a nucleic acid–binding dye. On initiation of
apoptosis and caspase-3/7 activation, the dye is cleaved
from the DEVD peptide and binds DNA, producing fluo-
rescence emission that can be detected at 520 nm. In
contrast to untreated cells, Panc-1 cells treated with 10
mol/L AIM-100 for 48 hours exhibited significant in-
crease in green fluorescence–producing cells (Figure 4,
G and H). Collectively, these data suggest that AIM-100
treatment arrests cells in the G1 phase, causes apopto-
sis, and, thus, inhibits pancreatic cancer cell growth.
Discussion
Recent studies underscore the oncogenic role of Ack1/
TNK2 in breast and prostate cancer.16 Of importance in
biopsy samples of human primary breast and prostate
cancer, Ack1 activation positively correlates with breast
cancer progression, and negatively with patient sur-
vival.15,19 Consistent with these data, Ewing’s sarcomas
cells seem to require Tnk2/Ack1 for growth and sur-
vival.23 In the present study, we demonstrated for the first
time that PanIN and pancreatic adenocarcinomas also
exhibit significantly higher levels of pTyr284-Ack1 or ac-
tivated Ack1, which correlate with poor prognosis. The
substantial activation of Ack1 in these tumors is likely the
consequence of more than one growth factor–activated
RTK signaling pathway feeding into Ack1, as is evident in
that Ack1 can be activated by more than one ligand, for
example, EGF and insulin. In addition to these, othermechanisms of Ack1 activation could also be operational
in pancreatic cancer. Ack1 gene amplification, another
mechanism of Ack1 activation, has been reported in lung
and prostate cancers.20 Also, Ack1 may be activated by
somatic auto-activating mutations. Second-generation
sequencing from our laboratory and those of others has
identified more than a dozen auto-activating mutations in
lung, ovarian, and stomach cancers (four of eight muta-
tions have been published15). Whether somatic auto-ac-
tivating mutations occur in Ack1/Tnk2 in pancreatic can-
cer is not known. We are currently sequencing pancreatic
primary tumor biopsy samples for Ack1 auto-activating
mutations and gene amplifications.
We observed high levels of pTyr284-Ack1 but signifi-
cantly lower levels of pTyr176-AKT in PanIN. PanIN is an
early precancerous lesion. Inasmuch as Ack1 kinase is a
“driver,” high pTyr284-Ack1 levels can be detected in
PanIN because of its early activation. However, optimal
Tyr176-phosphorylation of AKT has not yet been
achieved in PanIN, which could be why significantly
lower levels of pTyr176-AKT were observed.
While AKT is active in many pancreatic tumors, direct
nucleotide sequencing of AKT2, PIK3CA, RPS6K1,
STK11, PDPK1, and FRAP1-mTOR, which are six key
genes of the AKT/mTOR (mammalian target of rapamy-
cin) pathway, revealed no mutations in 36 primary pan-
creatic endocrine tumors.24 Whether these tumor biopsy
samples harbor Ack1-activating mutations is not known.
We found it striking that 96% of the pancreatic endocrine
tumors (135 of 140) were immunopositive for PDGFR-,
another RTK that activates Ack1.16 Our immunohisto-
chemistry analysis has revealed significant expression of
Tyr176-phosphorylated AKT in carcinomas, which sug-
gests the possibility that the Ack1/AKT signaling nexus
may be operational in pancreatic cancers. Because ac-
tivated Ack1 maintains active AKT pools even in the pres-
ence of PI3K inhibitors,15 the present study highlights the
importance of PI3K-independent pathways in AKT acti-
vation in pancreatic tumors and may explain the resis-
tance of pancreatic cancers to PI3K inhibitors.
Our data suggest that in addition to AKT, Ack1 may
require additional proteins to promote survival. One of the
major downstream effecters of Ack1 is tumor-suppressor
Wwox (WW domain-containing oxidoreductase).17,25,26
We have demonstrated that Ack1 phosphorylates Wwox
at Tyr 287, leading to its polyubiquitination and degrada-
tion.17 Thus, Ack1 could stimulate pancreatic cancer pro-
gression by positively regulating oncogenic kinase AKT
and negatively regulating the pro-apoptotic tumor sup-
pressor Wwox. Further studies will be needed to assess
the precise contributions of these two signaling events.
In conclusion, we have demonstrated for the first time
a functional role for the Ack1/AKT signaling nexus in
progression of pancreatic cancer. Further, we have gen-
erated rabbit monoclonal antibodies that specifically rec-
ognize pTyr176-AKT. Availability of this important re-
search resource enabled us to assess loss of AKT
Tyr176-phosphorylation on treatment with the Ack1 inhib-
itor AIM-100. AIM-100 not only inhibited Ack1/AKT Tyr-
phosphorylation but also suppressed growth of cell lines
derived from pancreatic, breast, and lung tumors. Con-
Ack1/AKT Activation in Pancreatic Cancer 1393
AJP April 2012, Vol. 180, No. 4sidered together, these data highlight the clinical rele-
vance of targeted inhibition of Ack1 signaling for sup-
pression of pancreatic cancer. Results of this study have
clinical implications because they offer a new drug target
for therapeutic intervention in pancreatic cancer.
Acknowledgments
We thank Dr. Alexis Lopez for pathologic scoring of the
TMA immunostaining, Dr. Mokenge Malafa for providing
HPNE cells, and Sridevi Challa, Jeremy McGuire, and
Noopur Ghade for technical assistance.
References
1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer Statistics, 2000.
CA Cancer J Clin 2000, 50:7–33
2. Burris H 3rd, Rocha-Lima C: New therapeutic directions for advanced
pancreatic cancer: targeting the epidermal growth factor and vascu-
lar endothelial growth factor pathways. Oncologist 2008, 13:289–298
3. Xiong HQ, Abbruzzese JL: Epidermal growth factor receptor–
targeted therapy for pancreatic cancer. Semin Oncol 2002, 29:31-37
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au
HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G,
Voskoglou-Nomikos T, Ptasynski M, Parulekar W: Erlotinib plus gem-
citabine compared with gemcitabine alone in patients with advanced
pancreatic cancer: a phase III trial of the National Cancer Institute of
Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960–1966
5. Manning BD, Cantley LC: AKT/PKB signaling: navigating down-
stream. Cell 2007, 129:1261–1274
6. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR: Activation of AKT
kinases in cancer: implications for therapeutic targeting. Adv Cancer
Res 2005, 94:29–86
7. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT path-
way in human cancer. Nature Rev 2002, 4:489–501
8. Greer EL, Brunet A: FOXO transcription factors at the interface be-
tween longevity and tumor suppression. Oncogene 2005, 24:7410–
7425
9. Huang H, Tindall DJ: Dynamic FoxO transcription factors. J Cell Sci
2007, 120:2479–2487
10. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ: Inci-
dence, mechanism and prognostic value of activated AKT in pan-
creas cancer. Br J Cancer 2003, 89:2110–2115
11. Matsumoto J, Kaneda M, Tada M, Hamada J, Okushiba S, Kondo S,
Katoh H, Moriuchi T: Differential mechanisms of constitutive Akt/PKB
activation and its influence on gene expression in pancreatic cancer
cells. Jpn J Cancer Res 2002, 93:1317–1326
12. Sakurada A, Suzuki A, Sato M, Yamakawa H, Orikasa K, Uyeno S,
Ono T, Ohuchi N, Fujimura S, Horii A: Infrequent genetic alterations of
the PTEN/MMAC1 gene in Japanese patients with primary cancers of
the breast, lung, pancreas, kidney, and ovary. Jpn J Cancer Res
1997, 88:1025–1028
13. Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, Moses T,
Carpten JD: PI3K/AKT pathway activation in acute myeloid leukae-mias is not associated with AKT1 pleckstrin homology domain
mutation. Br J Haematol 2008, 140:344–347
14. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang
W, Smith TL, Shi D, Yu D: Activation of the Akt/mammalian target of
rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor
progression in breast cancers. Clin Cancer Res 2004, 10:6779–6788
15. Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS,
Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ,
Schonbrunn E, Sebti SM, Earp HS, Mahajan NP: Ack1 mediated
AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS
One 2010, 5:e9646
16. Mahajan K, Mahajan NP: Shepherding AKT and androgen receptor
by Ack1 tyrosine kinase. J Cell Physiol 2010, 224:327–333
17. Mahajan NP, Whang YE, Mohler JL, Earp HS: Activated tyrosine
kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyu-
biquitination of tumor suppressor Wwox. Cancer Res 2005, 65:
10514–10523
18. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL,
Earp HS, Whang YE: Activated Cdc42-associated kinase Ack1 pro-
motes prostate cancer progression via androgen receptor tyrosine
phosphorylation. Proc Natl Acad Sci USA 2007, 104:8438–8443
19. Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, Zhu
W, Chen YA, Lawrence NJ, Mahajan NP: Effect of Ack1 tyrosine
kinase inhibitor on ligand-independent androgen receptor activity.
Prostate 2010, 70:1274–1285
20. van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, Orf J,
Rong M, Li S, See LH, Nguyen KQ, Hoey T, Wesche H, Powers S:
Metastatic properties and genomic amplification of the tyrosine ki-
nase gene ACK1. Proc Natl Acad Sci USA 2005, 102:15901–15906
21. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS,
Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N,
Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy
A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers
CL, Gerald WL: Integrative genomic profiling of human prostate can-
cer. Cancer Cell 2010, 18:11–22
22. DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan
JL, Buckner WH, Cheng A, Faust T, Hsieh F, Huang X, Lee JH,
Marshall TL, Martin MW, McGowan DC, Schneider S, Turci SM, White
RD, Zhu X: Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as
inhibitors of Lck: development of an expedient and divergent syn-
thetic route and preliminary SAR. Bioorganic Med Chem Lett 2007,
17:2305–2309
23. Arora S, Bisanz KM, Peralta LA, Basu GD, Choudhary A, Tibes R,
Azorsa DO: RNAi screening of the kinome identifies modulators of
cisplatin response in ovarian cancer cells. Gynecol Oncol 2010,
118:220–227
24. Corbo V, Beghelli S, Bersani S, Antonello D, Talamini G, Brunelli M,
Capelli P, Falconi M, Scarpa A: Pancreatic endocrine tumours: mu-
tational and immunohistochemical survey of protein kinases reveals
alterations in targetable kinases in cancer cell lines and rare prima-
ries. Ann Oncol 2011, 23:127–134
25. Sudol M, Recinos CC, Abraczinskas J, Humbert J, Farooq A: WW or
WoW: the WW domains in a union of bliss. IUBMB Life 2005, 57:773–
778
26. Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky
Y, Sudol M, Croce CM: WW domain-containing proteins, WWOX and
YAP, compete for interaction with ErbB-4 and modulate its transcrip-
tional function. Cancer Res 2005, 65:6764–6772
